Rapport Therapeutics, Inc. Common StockRAPPNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+118.3%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+118.3%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
10.4x
Strong expansion
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$94.79M+55.6%
2024$60.94M+117.6%
2023$28.00M+207.2%
2022$9.12M-